Scienmag

MAY 26, 2021

A […].

Immune Response 54

Immune Response Protein Vaccination Vaccine 54

Pharmaceutical Technology

MAY 17, 2023

It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body. Together, we will now ramp up production under high pressure to roll out supply in order to serve the patient population in need as soon as possible.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

Drug Discovery World

MAY 15, 2024

For example, the new vaccine does not include the SARS-CoV-1 coronavirus, which caused the 2003 SARS outbreak, yet it still induces an immune response to that virus. Chains of different viral antigens are attached to this nanoparticle using a novel ‘protein superglue’.

Vaccination 52

Vaccination Vaccine Immune Response Clinical Trials 52

Drug Discovery World

OCTOBER 5, 2023

Evozyne has closed an $81 million Series B investment round that will fund the biotech’s generative AI-powered drug discovery platform and product development. “In In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability.

Drugs 52

Drugs Immune Response Protein Gene 52

Drug Discovery World

FEBRUARY 19, 2024

At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus. Preliminary data show that the surrogate metric of protection (RVNA≥0.5)

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Drug Discovery World

AUGUST 3, 2023

Bimervax from HIPRA Human Health has been authorised in the UK after meeting the Medicines & Healthcare products Regulatory Agency’s (MHRA) required safety, quality and effectiveness standards. Bimervax combines a part of the SARS-CoV-2 virus spike protein with an adjuvant.

Vaccination 52

Vaccination Vaccine Immune Response Medicine 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. The company will work with Medsafe, New Zealand’s regulatory agency, to obtain product approvals as needed.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion CEO Per Norlén said: “We believe that ExpreS 2 ion´s superb platforms for the production of complex proteins are a great match with our AI platform for target discovery and our novel technologies for inducing strong immune responses.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

APRIL 18, 2023

Innovation S-curve for the pharmaceutical industry HIV peptides is a key innovation area in pharmaceuticals HIV peptides are fragments derived from HIV envelope gp160 protein, the HIV matrix/capsid proteins, and the HIV gag, pol and env gene products. These can serve as an important component of a vaccine.

Protein 147

Protein Vaccination Vaccine Production 147

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. The mRNA constructs used in COVID-19 vaccines, for example, direct cells to produce a version of the “spike” protein studding the surface of SARS-CoV-2.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

XTalks

JUNE 15, 2022

Last week, Novavax announced that it received positive feedback from the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the safety and efficacy of its COVID-9 vaccine (NVX-CoV2373). protein that triggers the immune system to generate antibodies against the virus.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

The Pharma Data

APRIL 15, 2022

Each serum was tested simultaneously for its neutralizing titer against recombinant SARS-CoV-2 (with USA-WA-1/2020 genetic backbone) bearing the wild-type SARS-CoV-2 spike protein and theOmicron spike. The 50% neutralizing geometric mean titer (GMT) against Omicron was 993 (after three doses), compared to 27 after two doses.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

Camargo

JULY 27, 2021

It is a comprehensive term which encompasses a large variety of therapy products including viral and bacterial vectors, plasmid DNA, human gene editing technology, and patient-specific cellular gene therapy. Gene Therapy Definition. Gene therapy is a new therapeutic approach in which genes are used to treat or prevent diseases.

Gene Therapy 238

Gene Therapy Gene Gene Editing Genetics 238

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 59

Research Immune Response Antibody Medicine 59

Cloudbyz

MARCH 5, 2024

The difference between biologics vs small molecules in pharma drug development In pharmaceutical drug development, biologics and small molecules represent two distinct categories of medicinal products, each with their own unique characteristics, development processes, and mechanisms of action.

Development 77

Development Drugs Manufacturing Immune Response 77

XTalks

NOVEMBER 6, 2020

Symvivo’s bacTRL Gene Therapy Platform is designed and optimized to address limitations associated with typical vaccines, including the inability to accommodate large or multiple genes, lack of specificity to targeted tissue and poor control over immune response, says the company.

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

Clinical Trials 52

Clinical Trials Clinical Trials Pharma Companies Vaccination 52

XTalks

OCTOBER 12, 2021

The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. is an autoantigen, which means it is an endogenous antigen that triggers an immune response in the body. as a potential trigger for rheumatoid arthritis. They found that 14-3-3?

Vaccination 105

Vaccination Vaccine Research Immune Response 105

The Pharma Data

MARCH 8, 2022

Like other members of this genus, SARS-CoV-2 is equipped with several molecular tools that allow it to evade recognition by the immune system. The virus carries the information to produce a series of proteins, capable of inhibiting antiviral recognition systems of the infected cell. Mouse model to resemble human COVID-19 infection.

Immune Response 52

Immune Response RNA Protein Genetics 52

pharmaphorum

MARCH 3, 2021

Novavax’s vaccine is a sequence of protein engineered from the genetic sequence of the SARS-CoV-2 virus that mimics the “Spike” protein found on the pathogen’s surface. It cannot replicate or cause the disease but does produce a strong immune response that neutralises the virus in the event of an infection.

Vaccination 130

Vaccination Vaccine Regulation Immune Response 130

pharmaphorum

DECEMBER 22, 2020

There is no evidence to suggest the new strain causes more serious illness, but it does show variations in the “spike” protein that the virus uses to infect cells – the same protein that the Pfizer/BioNTech shot uses to confer immunity. The likelihood that our vaccine works … is relatively high.”.

Vaccination 81

Vaccination Vaccine Protein Immune Response 81

Drug Discovery World

AUGUST 16, 2023

The antibody, called Ab-IPL-IL-17, targets a specific section of signalling proteins IL-17A and IL-17F which play a central role in sustaining inflammation during onset and progression of autoimmune diseases.

Antibody 52

Antibody Immune Response Protein Research 52

XTalks

DECEMBER 20, 2021

Covovax is a recombinant protein-based vaccine and can be regarded as a more “traditional” vaccine as it isn’t genetic-based like mRNA or viral vector vaccines. Covovax is a protein subunit vaccine developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI).

Vaccination 96

Vaccination Vaccine Manufacturing Protein 96

pharmaphorum

NOVEMBER 28, 2021

Omicron has more mutations affecting the spike protein targeted by vaccines than any other strain identified to date – up to 32 mutations versus eight for the Delta variant – but its not clear how that will affect the transmissibility and virulence of the virus. 1.1.529 version of its recombinant protein-based shot.

Vaccination 111

Vaccination Vaccine Protein Genetics 111

Pharmaceutical Technology

FEBRUARY 3, 2023

In Imbokodo, two parts of the immune response seemed to correlate with protection, one of which is the activity of antibodies to the V1 and V2 regions of the envelope protein, says Susan Zolla-Pazner, PhD, professor of medicine at the Icahn School of Medicine at Mount Sinai, New York City.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Drug Discovery World

JULY 5, 2023

MG: I am responsible for Agilent’s cancer segment. You could describe my role as being a convener across all our cancer research-related product lines, our Medical Affairs team, and the rest of the organisation. Of course, if a patient’s tumour does not have this protein, then this type of treatment won’t be effective.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

JULY 25, 2023

Two years after this discovery, his team was able to show that the LAG-3 protein was a ligand for MHC Class II molecules like CD4. Immutep, listed on ASX and NASDAQ, is a pure-play LAG-3 company, with five product candidates in development. Triebel reported the first cloning of the LAG-3 gene in 1990. In 1998, Triebel et al.

Immune Response 98

Immune Response Gene Protein Antibody 98

Cloudbyz

MARCH 6, 2024

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Personalized Medicine: Biologics offer the potential for personalized treatment approaches by taking into account individual variations in genetics, immune responses, and disease characteristics.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

pharmaphorum

MARCH 17, 2022

.” Both Pfizer’s BioNTech-partnered Comirnaty and Moderna’s SpikeVax vaccines use LNPs to carry mRNA coding for the SARS-CoV-2 spike protein. After dosing, the LNPs deliver the mRNA sequence into cells, which is then used by cellular machinery to manufacture the viral protein and stimulate an immune response.

Vaccination 52

Vaccination Vaccine Sales Immune Response 52

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Immune Response 64

Immune Response Vaccination Vaccine Gene Sequencing 64

pharmaphorum

AUGUST 23, 2021

DNA vaccines work by delivering a genetically-engineered plasmid containing the DNA sequence encoding the desired antigen – in this case the SARS-CoV-2 spike protein – which is then taken up by cells. Proponents of the approach claim that DNA vaccines may have advantages over other technologies like mRNA.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

SEPTEMBER 21, 2023

The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. This vaccine utilizes the human CMV vector platform and is designed to prompt the production of T cells within the body. Vir Biotechnology, Inc., mRNA, 2) BG505 MD39.3

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

FEBRUARY 9, 2022

The oncology segment has been recognised as one of the most productive areas for pharmaceutical companies to focus their R&D investment. While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response. over the last five years.

Vaccination 134

Vaccination Vaccine Clinical Trials Clinical Trials 134